InfuSystem Holdings, Inc. Reports Third Quarter 2019 Financial Results
Increases of 28.9% in Revenue, 318.7% in Net Income and 57.3% in Adjusted EBITDA vs. Same Prior Year Period; Raises 2019 and 2020 Targets
MADISON HEIGHTS, Michigan, Nov. 13, 2019 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American LLC: INFU) (“InfuSystem” or the “Company”), a leading national durable medical equipment (“DME”) solutions provider for manufacturers and health care providers in the United States and Canada, today reported financial results for the third quarter ended September 30, 2019.
Third Quarter Highlights:
- Net revenues for the three and nine months ended September 30, 2019 were $21.5 million and $59.4 million, respectively, a $4.8 million, or 28.9%, increase and $9.8 million, or 19.8%, increase, respectively, from the same prior year periods.
- Net income for the quarter and year-to-date ended September 30, 2019 was $1.1 million and $0.6 million, respectively, compared to a net loss for the quarter and year-to-date ended September 30, 2018 of $0.5 million and $0.8 million, respectively.
- Adjusted earnings before interest, income taxes, depreciation, and amortization (“Adjusted EBITDA”) for the three and nine months ended September 30, 2019 was $5.2 million and $12.8 million, respectively, a $1.9 million, or 57.3%, increase and a $2.8 million, or 27.8%, increase, respectively, from the same prior year periods.
- Net cash flows provided by operating activities were $9.5 million year-to-date, an increase of $1.3 million, or 16.1%, from the same prior year period.
Commenting on the third quarter, Richard DiIorio, chief executive officer of InfuSystem, said, “The growth we have discussed in prior periods continues to meet or exceed our plans, primarily related to the impact of the market share gains in our oncology business that began last year with elastomerics and is continuing this year with wins from our direct competitor in that therapy. We also continue to benefit from growth in our pain management and infusion products markets, with the third quarter being an especially strong quarter in product sales. Our disciplined approach to managing this growth has enabled us to enjoy similar improvements in our EBITDA and net cash flow provided by operations.”
Mr. DiIorio continued, “It is rewarding to see our strategic plan and operating improvements being reflected in the performance of our stock price over recent months. I am especially proud of our team’s continued ability to execute on our significant growth initiatives while improving profitability.”
Mr. DiIorio concluded, “I am confident that the management team changes we announced in October will enable us to accelerate and expand growth in our Integrated Therapies Platform which currently includes our oncology and pain management programs. We are finalizing our plans for 2020, but as part of our expanded offerings we expect to, starting in the fourth quarter of 2019 or the first quarter of 2020, provide modified segment reporting to improve visibility into the operations of our two business platforms, Integrated Therapies and DME Services.”
InfuSystem updated its revenue and EBITDA targets for fiscal years 2019 and 2020. In the current year ending December 31, 2019, the Company currently expects $79.0 million in total revenue and $17.5 million in Adjusted EBITDA; this is up from the targets of $74.0 million in revenue and $16.0 million in Adjusted EBITDA previously communicated. For the fiscal year ending December 31, 2020, the Company currently expects $89.0 million plus in revenue and $22.0 million plus in Adjusted EBITDA; this is up from the targets of $85.0 million in revenue and $21.0 million plus in Adjusted EBITDA previously communicated.
Conference Call
The Company will conduct a conference call for investors on Wednesday, November 13, 2019 at 9:00 a.m. Eastern Time to discuss second quarter 2019 results. The conference call may also include a discussion of Company developments, forward-looking statements and other material information about business and financial matters. To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the investors section of the Company’s website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ for the next 90 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10136542, through November 20, 2019.
Condensed Consolidated Financial Statements
Certain balances in the condensed consolidated financial statements for the quarter and year-to-date ended September 30, 2018 have been reclassified to be consistent with the quarter and year-to-date ended September 30, 2019 presentation in accordance with GAAP.
Non-GAAP Measures
This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because they allow them to understand and compare the Company's operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring items that are not part of the normal course of business and that the Company’s management does not believe will have similar comparable year-over-year items or for non-operating items. A reconciliation of those measures to the most directly comparable GAAP measures is provided below.
This press release also contains future period non-GAAP guidance. Future period non-GAAP guidance includes adjustments for non-recurring or non-operating items, which may include, without limitation, items included in the reconciliation below. Such adjustments may be affected by changes in ongoing assumptions and judgements, as well as non-recurring, unusual or unanticipated charges, expenses or gains or other items that may not directly correlate to the underlying performance of the Company’s business operations. The exact amounts of these adjustments are not currently determinable, but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP guidance to the most comparable GAAP measures.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related DME support services to hospitals, clinics and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. The Company’s stock is traded on the NYSE American LLC under the symbol INFU.
Forward-Looking Statements
The financial results in this press release reflect preliminary results, which are not final until the Company's Form 10-Q for the quarter ended September 30, 2019 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, business plans, objectives and prospects, and future operating or financial performance. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law and other risk factors disclosed in the Company’s most recent annual report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
FINANCIAL TABLES FOLLOW
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| As of | |||||||
| September 30, | December 31, | ||||||
| (in thousands, except share data) | 2019 | 2018 | |||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 3,157 | $ | 4,318 | |||
| Accounts receivable, net | 11,462 | 9,593 | |||||
| Inventories | 2,768 | 2,254 | |||||
| Other current assets | 1,605 | 1,372 | |||||
| Total current assets | 18,992 | 17,537 | |||||
| Medical equipment for sale or rental | 2,051 | 1,601 | |||||
| Medical equipment in rental service, net of accumulated depreciation | 32,269 | 23,488 | |||||
| Property & equipment, net of accumulated depreciation | 2,845 | 1,445 | |||||
| Intangible assets, net | 16,539 | 19,865 | |||||
| Operating lease right of use assets | 5,004 | ||||||
| Other assets | 195 | 137 | |||||
| Total assets | $ | 77,895 | $ | 64,073 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 10,669 | $ | 7,091 | |||
| Current portion of long-term debt | 7,009 | 4,903 | |||||
| Other current liabilities | 4,136 | 2,796 | |||||
| Total current liabilities | 21,814 | 14,790 | |||||
| Long-term debt, net of current portion | 30,342 | 28,842 | |||||
| Deferred income taxes | 76 | - | |||||
| Operating lease liabilities, net of current portion | 3,944 | - | |||||
| Total liabilities | 56,176 | 43,632 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued | - | - | |||||
| Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,356,308 and 19,837,819, respectively, as of September 30, 2019 and 23,095,513 and 19,577,024, respectively, as of December 31, 2018 | 2 | 2 | |||||
| Additional paid-in capital | 83,889 | 83,167 | |||||
| Retained deficit | (62,172 | ) | (62,728 | ) | |||
| Total stockholders’ equity | 21,719 | 20,441 | |||||
| Total liabilities and stockholders’ equity | $ | 77,895 | $ | 64,073 | |||
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
|
Three Months Ended |
Nine Months Ended |
||||||||||||||
| (in thousands, except share and per share data) |
September 30 |
September 30 |
|||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Net revenues | $ | 21,489 | $ | 16,677 | $ | 59,405 | $ | 49,575 | |||||||
| Cost of revenues | 9,251 | 7,003 | 25,470 | 19,978 | |||||||||||
| Gross profit | 12,238 | 9,674 | 33,935 | 29,597 | |||||||||||
| Selling, general and administrative expenses: | |||||||||||||||
| Amortization of intangibles | 1,077 | 1,160 | 3,326 | 3,512 | |||||||||||
| Selling and marketing | 2,402 | 2,323 | 7,480 | 6,950 | |||||||||||
| General and administrative | 7,096 | 6,286 | 20,915 | 18,846 | |||||||||||
| Total selling, general and administrative | 10,575 | 9,769 | 31,721 | 29,308 | |||||||||||
| Operating income (loss) | 1,663 | (95 | ) | 2,214 | 289 | ||||||||||
| Other expense: | |||||||||||||||
| Interest expense | (488 | ) | (370 | ) | (1,436 | ) | (981 | ) | |||||||
| Other expense | (11 | ) | (9 | ) | (71 | ) | (19 | ) | |||||||
| Income (loss) before income taxes | 1,164 | (474 | ) | 707 | (711 | ) | |||||||||
| Provision for income taxes | (29 | ) | (45 | ) | (151 | ) | (109 | ) | |||||||
| Net income (loss) | $ | 1,135 | $ | (519 | ) | $ | 556 | $ | (820 | ) | |||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | 0.06 | $ | (0.03 | ) | $ | 0.03 | $ | (0.04 | ) | |||||
| Diluted | 0.05 | (0.03 | ) | 0.03 | (0.04 | ) | |||||||||
| Weighted average shares outstanding: | |||||||||||||||
| Basic | 19,781,527 | 20,672,688 | 19,690,737 | 22,043,213 | |||||||||||
| Diluted | 20,679,431 | 20,672,688 | 20,503,933 | 22,043,213 | |||||||||||
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
|
Nine Months Ended |
|||||||
|
September 30 |
|||||||
| (in thousands) | 2019 | 2018 | |||||
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $ | 9,534 | $ | 8,210 | |||
| INVESTING ACTIVITIES | |||||||
| Purchase of medical equipment, property and equipment | (16,420 | ) | (4,521 | ) | |||
| Proceeds from sale of medical equipment, property and equipment | 2,239 | 2,344 | |||||
| NET CASH USED IN INVESTING ACTIVITIES | (14,181 | ) | (2,177 | ) | |||
| FINANCING ACTIVITIES | |||||||
| Principal payments on term loans, capital lease obligations and other financing | (3,915 | ) | (5,048 | ) | |||
| Cash proceeds from other financing | 7,462 | 9,660 | |||||
| Debt issuance costs | (3 | ) | (27 | ) | |||
| Common stock repurchased to satisfy statutory withholding on employee stock based compensation plans | (295 | ) | (5 | ) | |||
| Common stock repurchased as part of Repurchase Program | - | (10,291 | ) | ||||
| Cash proceeds from stock plans | 237 | 91 | |||||
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | 3,486 | (5,620 | ) | ||||
| Net change in cash and cash equivalents | (1,161 | ) | 413 | ||||
| Cash and cash equivalents, beginning of period | 4,318 | 3,469 | |||||
| Cash and cash equivalents, end of period | $ | 3,157 | $ | 3,882 | |||
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
(UNAUDITED)
| NET INCOME (LOSS) TO ADJUSTED EBITDA: | ||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||
| September 30 | September 30 | |||||||||||||
| (in thousands) | 2019 | 2018 | 2019 | 2018 | ||||||||||
| GAAP net income (loss) | $ | 1,135 | $ | (519 | ) | $ | 556 | $ | (820 | ) | ||||
| Adjustments: | ||||||||||||||
| Interest expense | 488 | 370 | 1,436 | 981 | ||||||||||
| Income tax provision | 29 | 45 | 151 | 109 | ||||||||||
| Depreciation | 2,051 | 1,626 | 5,727 | 4,879 | ||||||||||
| Amortization | 1,077 | 1,160 | 3,326 | 3,512 | ||||||||||
| Non-GAAP EBITDA | $ | 4,780 | $ | 2,682 | $ | 11,196 | $ | 8,661 | ||||||
| Stock compensation costs | 250 | 288 | 780 | 679 | ||||||||||
| Early termination fees for capital leases | - | - | 190 | - | ||||||||||
| Shareholder costs | - | 86 | - | 233 | ||||||||||
| Exited facility costs | - | - | 6 | 44 | ||||||||||
| Management reorganization/transition costs | 6 | 72 | 51 | 209 | ||||||||||
| ASC 842 accounting principle change | 108 | - | 216 | - | ||||||||||
| Certain other non-recurring costs | 24 | 158 | 371 | 198 | ||||||||||
| Non-GAAP Adjusted EBITDA | $ | 5,168 | $ | 3,286 | $ | 12,810 | $ | 10,024 | ||||||
| GAAP Net Revenues | $ | 21,489 | $ | 16,677 | $ | 59,405 | $ | 49,575 | ||||||
| GAAP Net Income Margin | 5.3% | -3.1% | 0.9% | -1.7% | ||||||||||
| Non-GAAP Adjusted EBITDA Margin | 24.0% | 19.7% | 21.6% | 20.2% | ||||||||||
Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues.
| CONTACT: | Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC 602-889-9700 |
Released November 13, 2019
